Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- PAC Machinery to Showcase Packaging Equipment, Sustainable Materials, and Flexible Packaging Solutions at PACK EXPO International 2026PAC Machinery will showcase packaging automation, sustainable materials, and flexible packaging solutions at PACK EXPO International 2026.
- CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)SHENZHEN, CHINA - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for the treatment of mild to moderate atopic dermatitis (“AD”) on 2 September 2026. The drug registration certificate was obtained on 3 September 2026. The product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA for indication AD has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which effectively shortened the product's review process and accelerated the marketing approval for the AD indication. From “First Topical JAK Inhibitor” to Indication Expansion, Lumirix® Continues to Deliver Clinical Value In January 2026, Lumirix® was approved for marketing by the NMPA, becoming the first topical JAK inhibitor approved in China for the treatment of vitiligo. The approval of this NDA for the additional indication of AD offers a novel treatment option for pediatric patients 2 years of age and older, adolescent and adult AD patients, with safety and efficacy supported by clinical data*. Previously, Lumirix® achieved positive results in a randomized, double-blind, placebo-controlled phase III clinical trial in China for mild to moderate AD: · Robust Efficacy: Lumirix® successfully met its primary endpoint— a significantly higher proportion of patients treated with Lumirix® achieved IGA (Investigator's Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with Lumirix® was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). · Favorable Safety Profile: the severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, Lumirix® was safe and well-tolerated. *Based on Phase III clinical data from China and overseas. Building the AD “treatment + care” Solution to Strengthen Dermavon's Skin Health Layout AD is a chronic, recurrent and inflammatory dermatologic disease. According to CIC Report, there were over 54 million AD patients in China in 2024[1]. To address the needs of AD patients from treatment to daily care, Dermavon has built a comprehensive “treatment + care” solution: · Topical formulation: Lumirix® (mild-to-moderate AD) – Marketed in China · Injectable biological agent: Comekibart Injection (moderate-to-severe AD) – Under NDA review in China · Oral small molecule targeted drug: CMS-D001 (moderate-to-severe AD) – Phase II clinical trial · Daily repair: Heling Soothing Product Series – Marketed in China Simultaneously, the indication expansion of Lumirix® will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health. About AD AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream is a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in adult and pediatric patients 12 years of age and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, as well as the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate[3,4]. On 2 December 2022, Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream, obtaining an exclusive license to develop, register and commercialize the product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the product in the Territory. Dermavon has sublicensed the relevant rights for the product outside of Mainland China to the Group (excluding Dermavon). About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. References 1. China Insights Consultancy’s industrial report 2. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib 3. The EMA approval information for vitiligo indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 4. The EMA approval information for AD indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/opzelurar-ruxolitinib-cream-becomes-first-steroid-free-topical CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: [email protected]: https://web.cms.net.cn/en/home/
- FormerraFormerra Receives 2026 Eaton Supplier Excellence AwardROMEOVILLE, IL, Sept 4, 2026 - Formerra, a leader in performance materials distribution, was recognized for its partnership at Eaton's 2026 Global Supplier Conference & Excellence Awards, held Thursday, August 27 in Beachwood, Ohio. Formerra was one of only 30 suppliers recognized with Eaton's Supplier Excellence Award from among the company's global network of more than 30,000 supplier partners. Eaton grants the Supplier Excellence Award to suppliers that exceed expectations through exceptional performance, innovation, and contributions to growth. Formerra serves as Eaton's preferred plastics distribution partner, a role built through disciplined execution and engagement across Eaton's corporate organization and manufacturing sites. While the partnership began over 15 years ago in North America, it now extends into Asia, Europe, and the Middle East, where Formerra recently established dedicated logistics and warehousing capabilities in Dubai to support Eaton's expansion in the region. Formerra has broadened its support, extending beyond polymer distribution in response to Eaton's dynamic requirements. The scope now covers thermoset materials, finished goods distribution, supply chain optimization, global logistics, and technical application support. "Eaton holds its supply base to a high standard, and this recognition reflects work our teams do every day across three continents," said Tom Kelly, Chief Executive Officer, Formerra. "Our people earned it by understanding how Eaton operates, anticipating needs, and solving problems before they reach a production line. The relationship between Formerra and Eaton offers strengthened supply resiliency, reduced supply chain risk, vendor consolidation, and improved operational efficiency as Eaton continues to pursue global growth. Caption: (L to R) Mike Hibbs, Global Category Manager, Eaton; Susan Logue, Sr. Key Accounts Manager, Formerra; Tom Kelly, CEO, Formerra Key Details: Formerra received the Supplier Excellence Award at Eaton's annual supplier conference. Formerra was one of 30 suppliers recognized from a global network of more than 30,000. Formerra serves as Eaton's preferred plastics distribution partner across North America, Asia, Europe, and the Middle East. Formerra has established warehousing capabilities in Dubai to support Eaton's regional operations. Support extends beyond plastics distribution into thermoset materials, finished goods distribution, supply chain optimization, and global logistics. About Formerra Formerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com. Contact Media Relations Global & Americas: Jackie Morris Email: [email protected] Phone: 630.849.3620 SOURCE: Formerra
- CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)SHENZHEN, CHINA - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for the treatment of mild to moderate atopic dermatitis (“AD”) on 2 September 2026. The drug registration certificate was obtained on 3 September 2026. The product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA for indication AD has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which effectively shortened the product's review process and accelerated the marketing approval for the AD indication. From “First Topical JAK Inhibitor” to Indication Expansion, Lumirix® Continues to Deliver Clinical Value In January 2026, Lumirix® was approved for marketing by the NMPA, becoming the first topical JAK inhibitor approved in China for the treatment of vitiligo. The approval of this NDA for the additional indication of AD offers a novel treatment option for pediatric patients 2 years of age and older, adolescent and adult AD patients, with safety and efficacy supported by clinical data*. Previously, Lumirix® achieved positive results in a randomized, double-blind, placebo-controlled phase III clinical trial in China for mild to moderate AD: · Robust Efficacy: Lumirix® successfully met its primary endpoint— a significantly higher proportion of patients treated with Lumirix® achieved IGA (Investigator's Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with Lumirix® was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). · Favorable Safety Profile: the severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, Lumirix® was safe and well-tolerated. *Based on Phase III clinical data from China and overseas. Building the AD “treatment + care” Solution to Strengthen Dermavon's Skin Health Layout AD is a chronic, recurrent and inflammatory dermatologic disease. According to CIC Report, there were over 54 million AD patients in China in 2024[1]. To address the needs of AD patients from treatment to daily care, Dermavon has built a comprehensive “treatment + care” solution: · Topical formulation: Lumirix® (mild-to-moderate AD) – Marketed in China · Injectable biological agent: Comekibart Injection (moderate-to-severe AD) – Under NDA review in China · Oral small molecule targeted drug: CMS-D001 (moderate-to-severe AD) – Phase II clinical trial · Daily repair: Heling Soothing Product Series – Marketed in China Simultaneously, the indication expansion of Lumirix® will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health. About AD AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream is a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in adult and pediatric patients 12 years of age and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, as well as the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate[3,4]. On 2 December 2022, Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream, obtaining an exclusive license to develop, register and commercialize the product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the product in the Territory. Dermavon has sublicensed the relevant rights for the product outside of Mainland China to the Group (excluding Dermavon). About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. References 1. China Insights Consultancy’s industrial report 2. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib 3. The EMA approval information for vitiligo indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 4. The EMA approval information for AD indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/opzelurar-ruxolitinib-cream-becomes-first-steroid-free-topical CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: [email protected] Website: https://web.cms.net.cn/en/home/
- How Long Does It Take to Program a Manufacturing Robot In 2026?GrayMatter Robotics data shows robotic systems operators train in one day, versus four to six months for manual finishers, thanks to Physical AI.
- Stellantis CEO Antonio Filosa to Participate in the 2026 Jefferies Global Industrials ConferenceCompanies: StellantisStellantis CEO Antonio Filosa will participate in a fireside chat at the 2026 Jefferies Global Industrials Conference in New York on September 10th.
- Northway BiotechFIRST IN THE BALTICS: NORTHWAY BIOTECH OPENS €61 MILLION CELL THERAPY AND PERSONALIZED MEDICINE CDMO IN VILNIUSBuilding on more than 22 years of CDMO experience across biologics and advanced therapies, Northway Biotech is significantly expanding its development and manufacturing capacity with a new 3,500 sq. m facility featuring up to 20 independent cGMP manufacturing lines and first customer...
- Xunce Technology Launches TokenCloud, Redefining the Value of Computing Power Through Full-Chain AI Infrastructure and Securing a Leading Position in the Token Economy EraHONG KONG, Sept 3, 2026 - On September 3, Xunce Technology (3317.HK) officially launched the TokenCloud all-in-one AI model training and deployment computing power platform. As the hardware resources and infrastructure that facilitate the conversion of data resources into tokens, TokenCloud builds a four-tier, synergistic ecosystem based on heterogeneous computing devices, powered by mainstream algorithmic models, fueled by multi-source internal and external data, and serving vertical industry clients. It is dedicated to establishing a full-chain value pathway from data to tokens, enabling every piece of data to securely and efficiently unlock its intelligent value, and helping industries across the board transform data resources into genuine AI productivity. The launch of TokenCloud marks Xunce Technology’s formal establishment of a full-chain product closed-loop encompassing “computing power—data—tokens—models—applications.” This achievement signifies a leap from a “digital foundation” to an “AI productivity platform,” securing a strategic vantage point in the token economy era while providing the industry with a model for AI infrastructure that bridges the entire “data-to-token” value chain. Building a Scenario-Driven, End-to-End Closed Loop to Provide Out-of-the-Box AI Infrastructure As enterprise AI applications shift from “proof of technical feasibility” to “competition in engineering efficiency,” systemic challenges—such as computing power shortages, difficulties in model selection, hardware compatibility issues, challenges in optimized deployment, and significant security concerns—are becoming the biggest bottlenecks hindering AI implementation. TokenCloud was created precisely to address these pain points. Positioned as the core “hardware and energy foundation” at the upstream of the token industry chain, it adheres to the principle of “ensuring every unit of computing power precisely serves every enterprise AI scenario.” It has built a complete closed-loop process spanning “scenario identification → model selection → hardware matching → training optimization → secure delivery.” Based on business scenarios and tasks, it intelligently recommends the optimal model and matches it with the most suitable hardware. It then uses distillation optimization to enable lightweight, “specialized” models to achieve accelerated inference with high accuracy, all the way through to secure delivery. With each step seamlessly linked, it provides enterprise customers with out-of-the-box AI infrastructure. In terms of product design, TokenCloud adopts a “full-chain visualization” philosophy, integrating the previously disparate processes of model selection, computing power configuration, security management, and cost assessment in AI deployment into a unified decision-making platform. Comprising five core modules—solution selection, model distillation, data security management, computing power acceleration, and computing resource management—this platform shifts enterprise AI deployment from “rule-of-thumb” approaches to “data-driven decision-making.” It ensures that the return on investment for every computing power allocation is clearly quantifiable, achieving a dynamic balance among performance, cost, and security. Four Core Capabilities Build Competitive Barriers and Enable Deep Synergy Between Models and Computing Power The actual value of a token is determined by four key metrics: first-character latency, generation speed, concurrent processing capacity, and service stability. Through Hardware-Software Co-Optimization, TokenCloud enables the large-scale supply of high-quality tokens—ensuring that every piece of data unleashes its maximum token value through the optimal combination of models and hardware. Specifically, TokenCloud has established industry-leading technological barriers through four core capabilities: a heterogeneous hardware platform, Cloud-Edge Collaboration Architecture, model evaluation and optimization, and secure isolation: Heterogeneous Hardware Platform—Integrates diverse computing resources such as GPUs, NPUs, FPGAs, and CPUs to enable unified management and intelligent scheduling across architectures. It supports full-scenario coverage ranging from hundreds to tens of thousands of cards, abstracting underlying, disparate hardware resources into unified computing units. Cloud-Edge Synergy Architecture—Establishes a hybrid deployment model combining “cloud computing power and on-premises computing power,” enabling elastic scaling to handle large-scale training and high-concurrency inference while ensuring that enterprises’ raw data remains within secure domains. This allows enterprises to enjoy cloud computing power while maintaining full data sovereignty at all times. Model Evaluation and Optimization System—Establishes a comprehensive evaluation framework covering foundational capabilities, scenario adaptation, engineering optimization, and ecosystem value. It supports task-specific distillation optimization, transferring the core capabilities of large models to lightweight scenario-specific models, thereby significantly reducing inference latency and hardware costs while maintaining high accuracy. Of particular importance is computing power acceleration—while chip computing power continues to rise, actual effective throughput remains far below theoretical peak values. Through end-to-end acceleration capabilities, TokenCloud significantly reduces first-token latency and enhances concurrent processing capacity, transforming acceleration cards from “waiting for computation” to “continuous computation.” This enables enterprises to support larger business volumes without additional hardware, achieving the optimal balance between accuracy, speed, cost, and deployment efficiency, and enabling the large-scale supply of high-quality tokens. Security Isolation Mechanism—We build a multi-layered security protection system where data visibility is tiered and data flow is fully traceable throughout its entire journey. Highly sensitive data is 100% locked within the enterprise’s local security domain, with a three-pronged approach combining multi-tenant isolation, encrypted transmission, and access control. Unlike simple computing power rental platforms or model service platforms on the market, TokenCloud achieves deep synergy between models and computing power—the platform centrally determines the degree of model distillation and the hardware for deployment, ensuring the optimal balance of accuracy, speed, cost, and efficiency. It provides enterprise customers with a comprehensive, one-stop service solution—from model selection and hardware matching to distillation optimization—covering the entire “computing power—data—Token—model—application” chain to accelerate the implementation of enterprise AI. Software and Hardware Synergy Closes the Full-Path Loop; Full-Stack AI Products Accelerate Industry Adoption The launch of TokenCloud has enabled Xunce Technology’s full-path product ecosystem to form a complete commercial loop. Previously, the company had introduced the world’s first TokenOS operating system; the two systems have clearly defined roles and operate in synergy. TokenOS focuses on data capabilities, transforming enterprises’ multi-source, heterogeneous data into standardized scenario-based Tokens in real time, thereby addressing the issue of “data usability.” TokenCloud focuses on model training and deployment, as well as “data + model” integration capabilities. It integrates computing power scheduling, model inference optimization, and the refinement, tuning, and orchestration of enterprise-level small models, bridging the entire chain from data ingestion to application deployment and providing hardware service support for Token generation. Through this synergy between software and hardware, combined with the underlying AIDP data resource processing service system and the top-level TokenRouters model outcomes service and scenario integration and exchange center, the two solutions together form a complete “computing power—data—Token—model—application” closed-loop ecosystem. This enables enterprises to significantly reduce deployment costs and improve matching efficiency through the synergy of computing power, data, and models. Xunce Technology has also undergone a comprehensive upgrade from an AI real-time data infrastructure service provider to an integrated AI-to-B infrastructure service provider. Furthermore, Xunce Technology has partnered with multiple domestic GPU manufacturers to focus on the integration of “computing power and data.” As the localization of the full AI stack enters the stage of systematic engineering optimization, TokenCloud has become a key hub connecting domestic heterogeneous computing power with enterprise AI applications, offering significant strategic value within the ecosystem. Currently, the company has expanded into eleven high-value industries, including finance, telecommunications, power, energy, high-end manufacturing, biomedicine, robotics training, commercial space, urban operations, the low-altitude economy, and smart vehicles. In the first half of 2026, the Token business model was successfully implemented in high-value scenarios such as biomedicine, energy dispatch, and industrial quality inspection, laying the groundwork for cross-industry replication. The ultimate goal of computing power is not to simply stack chips, but to ensure that every piece of data can be securely and efficiently converted into token value. As AI transitions from the “model competition” phase to the “deployment competition” phase, enterprises need not isolated computing power or isolated models, but rather an integrated infrastructure capable of combining computing power, data, and models to truly adapt to enterprise business scenarios. Positioned as an integrated AI infrastructure, TokenCloud enables computing power to serve models, models to serve scenarios, and scenarios to generate value, thereby laying a solid computing power foundation for the AI transformation of China’s myriad industries.
- Plus Automation, Inc.PlusAI, a Leader in Physical AI Pioneering AI-Based Virtual Driver Software for Factory-Built Autonomous Trucks, to Become Publicly Listed Through Business Combination with Texas Ventures Acquisition III CorpSANTA CLARA, Calif. & NEW YORK, September 03, 2026--Plus Automation, Inc. ("PlusAI"), a global physical AI company pioneering AI-based virtual driver software for factory-built autonomous trucks, and Texas Ventures Acquisition III Corp (Nasdaq: TVA, TVACU, TVACW) ("Texas Ventures III"), a special purpose acquisition company with financial backing from funds managed by Yorkville Advisors Global, LP ("Yorkville Advisors"), a global asset manager that has completed transactions valued at over $9 bi
- Xunce Technology Launches TokenCloud, Redefining the Value of Computing Power Through Full-Chain AI Infrastructure and Securing a Leading Position in the Token Economy EraHONG KONG, Sept 3, 2026 - On September 3, Xunce Technology (3317.HK) officially launched the TokenCloud all-in-one AI model training and deployment computing power platform. As the hardware resources and infrastructure that facilitate the conversion of data resources into tokens, TokenCloud builds a four-tier, synergistic ecosystem based on heterogeneous computing devices, powered by mainstream algorithmic models, fueled by multi-source internal and external data, and serving vertical industry clients. It is dedicated to establishing a full-chain value pathway from data to tokens, enabling every piece of data to securely and efficiently unlock its intelligent value, and helping industries across the board transform data resources into genuine AI productivity. The launch of TokenCloud marks Xunce Technology’s formal establishment of a full-chain product closed-loop encompassing “computing power—data—tokens—models—applications.” This achievement signifies a leap from a “digital foundation” to an “AI productivity platform,” securing a strategic vantage point in the token economy era while providing the industry with a model for AI infrastructure that bridges the entire “data-to-token” value chain. Building a Scenario-Driven, End-to-End Closed Loop to Provide Out-of-the-Box AI Infrastructure As enterprise AI applications shift from “proof of technical feasibility” to “competition in engineering efficiency,” systemic challenges—such as computing power shortages, difficulties in model selection, hardware compatibility issues, challenges in optimized deployment, and significant security concerns—are becoming the biggest bottlenecks hindering AI implementation. TokenCloud was created precisely to address these pain points. Positioned as the core “hardware and energy foundation” at the upstream of the token industry chain, it adheres to the principle of “ensuring every unit of computing power precisely serves every enterprise AI scenario.” It has built a complete closed-loop process spanning “scenario identification → model selection → hardware matching → training optimization → secure delivery.” Based on business scenarios and tasks, it intelligently recommends the optimal model and matches it with the most suitable hardware. It then uses distillation optimization to enable lightweight, “specialized” models to achieve accelerated inference with high accuracy, all the way through to secure delivery. With each step seamlessly linked, it provides enterprise customers with out-of-the-box AI infrastructure. In terms of product design, TokenCloud adopts a “full-chain visualization” philosophy, integrating the previously disparate processes of model selection, computing power configuration, security management, and cost assessment in AI deployment into a unified decision-making platform. Comprising five core modules—solution selection, model distillation, data security management, computing power acceleration, and computing resource management—this platform shifts enterprise AI deployment from “rule-of-thumb” approaches to “data-driven decision-making.” It ensures that the return on investment for every computing power allocation is clearly quantifiable, achieving a dynamic balance among performance, cost, and security. Four Core Capabilities Build Competitive Barriers and Enable Deep Synergy Between Models and Computing Power The actual value of a token is determined by four key metrics: first-character latency, generation speed, concurrent processing capacity, and service stability. Through Hardware-Software Co-Optimization, TokenCloud enables the large-scale supply of high-quality tokens—ensuring that every piece of data unleashes its maximum token value through the optimal combination of models and hardware. Specifically, TokenCloud has established industry-leading technological barriers through four core capabilities: a heterogeneous hardware platform, Cloud-Edge Collaboration Architecture, model evaluation and optimization, and secure isolation: Heterogeneous Hardware Platform—Integrates diverse computing resources such as GPUs, NPUs, FPGAs, and CPUs to enable unified management and intelligent scheduling across architectures. It supports full-scenario coverage ranging from hundreds to tens of thousands of cards, abstracting underlying, disparate hardware resources into unified computing units. Cloud-Edge Synergy Architecture—Establishes a hybrid deployment model combining “cloud computing power and on-premises computing power,” enabling elastic scaling to handle large-scale training and high-concurrency inference while ensuring that enterprises’ raw data remains within secure domains. This allows enterprises to enjoy cloud computing power while maintaining full data sovereignty at all times. Model Evaluation and Optimization System—Establishes a comprehensive evaluation framework covering foundational capabilities, scenario adaptation, engineering optimization, and ecosystem value. It supports task-specific distillation optimization, transferring the core capabilities of large models to lightweight scenario-specific models, thereby significantly reducing inference latency and hardware costs while maintaining high accuracy. Of particular importance is computing power acceleration—while chip computing power continues to rise, actual effective throughput remains far below theoretical peak values. Through end-to-end acceleration capabilities, TokenCloud significantly reduces first-token latency and enhances concurrent processing capacity, transforming acceleration cards from “waiting for computation” to “continuous computation.” This enables enterprises to support larger business volumes without additional hardware, achieving the optimal balance between accuracy, speed, cost, and deployment efficiency, and enabling the large-scale supply of high-quality tokens. Security Isolation Mechanism—We build a multi-layered security protection system where data visibility is tiered and data flow is fully traceable throughout its entire journey. Highly sensitive data is 100% locked within the enterprise’s local security domain, with a three-pronged approach combining multi-tenant isolation, encrypted transmission, and access control. Unlike simple computing power rental platforms or model service platforms on the market, TokenCloud achieves deep synergy between models and computing power—the platform centrally determines the degree of model distillation and the hardware for deployment, ensuring the optimal balance of accuracy, speed, cost, and efficiency. It provides enterprise customers with a comprehensive, one-stop service solution—from model selection and hardware matching to distillation optimization—covering the entire “computing power—data—Token—model—application” chain to accelerate the implementation of enterprise AI. Software and Hardware Synergy Closes the Full-Path Loop; Full-Stack AI Products Accelerate Industry Adoption The launch of TokenCloud has enabled Xunce Technology’s full-path product ecosystem to form a complete commercial loop. Previously, the company had introduced the world’s first TokenOS operating system; the two systems have clearly defined roles and operate in synergy. TokenOS focuses on data capabilities, transforming enterprises’ multi-source, heterogeneous data into standardized scenario-based Tokens in real time, thereby addressing the issue of “data usability.” TokenCloud focuses on model training and deployment, as well as “data + model” integration capabilities. It integrates computing power scheduling, model inference optimization, and the refinement, tuning, and orchestration of enterprise-level small models, bridging the entire chain from data ingestion to application deployment and providing hardware service support for Token generation. Through this synergy between software and hardware, combined with the underlying AIDP data resource processing service system and the top-level TokenRouters model outcomes service and scenario integration and exchange center, the two solutions together form a complete “computing power—data—Token—model—application” closed-loop ecosystem. This enables enterprises to significantly reduce deployment costs and improve matching efficiency through the synergy of computing power, data, and models. Xunce Technology has also undergone a comprehensive upgrade from an AI real-time data infrastructure service provider to an integrated AI-to-B infrastructure service provider. Furthermore, Xunce Technology has partnered with multiple domestic GPU manufacturers to focus on the integration of “computing power and data.” As the localization of the full AI stack enters the stage of systematic engineering optimization, TokenCloud has become a key hub connecting domestic heterogeneous computing power with enterprise AI applications, offering significant strategic value within the ecosystem. Currently, the company has expanded into eleven high-value industries, including finance, telecommunications, power, energy, high-end manufacturing, biomedicine, robotics training, commercial space, urban operations, the low-altitude economy, and smart vehicles. In the first half of 2026, the Token business model was successfully implemented in high-value scenarios such as biomedicine, energy dispatch, and industrial quality inspection, laying the groundwork for cross-industry replication. The ultimate goal of computing power is not to simply stack chips, but to ensure that every piece of data can be securely and efficiently converted into token value. As AI transitions from the “model competition” phase to the “deployment competition” phase, enterprises need not isolated computing power or isolated models, but rather an integrated infrastructure capable of combining computing power, data, and models to truly adapt to enterprise business scenarios. Positioned as an integrated AI infrastructure, TokenCloud enables computing power to serve models, models to serve scenarios, and scenarios to generate value, thereby laying a solid computing power foundation for the AI transformation of China’s myriad industries.
- Spartan Metals Corp.Spartan Metals Joins Defense Industrial Base Consortium as It Advances U.S. Tungsten and Critical Minerals PortfolioSpartan Metals Corp. (TSXV: W) (OTCQB: SPRMF) (FSE: J03) ("Spartan" or the "Company"), an exploration and development company focused on tungsten and critical minerals in the western United States, is pleased to announce that it has joined the Defense Industrial Base Consortium ("DIBC").The DIBC is a collaborative initiative focused on advancing secure, innovative, and resilient solutions for the nation's defense industrial...
- Sivers SemiconductorsSivers Semiconductors Invests USD 30 Million to Expand European Photonics Manufacturing for AI DatacentersGlasgow expansion will increase InP manufacturing capacity to more than 100 million CW DFB lasers annually, supporting anticipated AI infrastructure customer ramps — Sivers Semiconductors AB (STO: SIVE) today announced a USD 30 million strategic...